Intervention

Daratumumab SC

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting1

Common conditions4

Lead sponsors shown2

Clinical trials

2 shown

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman DiseaseNCT05907759 · 2024-07-10

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to DaratumumabNCT04270175 · 2021-04-14

ACTIVE_NOT_RECRUITING

Common conditions

AL Amyloidosis1 Amyloid1 Lymphoma, Primary Effusion1 Refractory AL Amyloidosis1

Leading sponsors

National Cancer Institute (NCI)1 Weill Medical College of Cornell University1

Trial status mix

ACTIVE_NOT_RECRUITING1

RECRUITING1

Phase mix

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.